August 6, 2018
Munich – Quarton International advised the sole shareholder of humediQ global GmbH (“humediQ”) on the sale of all shares to Varian Medical Systems, Inc. (“Varian”), a global leader in the radiotherapy of tumor diseases.
humediQ, headquartered in Munich, Germany, is focused on the development, production and sales of hardware and software solutions for quality assurance in radiotherapy. Key product of humediQ is IDENTIFY, an automated patient identification, positioning and motion management system for radiation therapy. IDENTIFY incorporates patient safety, quality, efficiency and surface-guided features in an automated workflow solution for surface-guided radiation therapy (SGRT). The IDENTIFY system features a palm reader for patient identification, a radio frequency identification (RFID) reader for proper accessory verification and placement on the treatment couch, automatic synchronization with the oncology information system, and SGRT cameras for proper patient positioning and motion monitoring throughout the treatment. For more information, visit www.humediq.com
Varian, headquartered in Palo Alto, California, is a leader in developing and delivering hardware and software products for the treatment of cancer with radiotherapy, stereotactic radiosurgery, stereotactic body radiotherapy (SBRT), proton therapy, and brachytherapy. Varian employs approximately 6,500 people around the world. For more information, visit www.varian.com
January 30, 2019
Finance Monthly Deal Maker Award for Quarton, a Cowen Company
To subscribe to our Newsletter, please use the following link.